From A1C to TIR – Rethinking Glycemic Targets for Better Long‑Term Outcomes

For decades, clinicians have relied on A1C as the primary benchmark for diabetes control. Yet many patients and providers now wonder: does a single quarterly number truly reflect daily glucose fluctuations and risks? As continuous glucose monitoring (CGM) becomes more accessible, the metric known as Time in Range (TIR) has emerged as a powerful complement — or even alternative — to A1C. Understanding TIR can transform how we assess and manage glycemic control, offering a more nuanced window into everyday glucose patterns and long-term risk.

Table of Contents

• What is Time in Range and why it matters
• Limitations of A1C that TIR can address
• How to interpret and apply TIR in clinical practice
• Evidence that TIR predicts long-term outcomes
• Challenges, limitations, and future directions
• Conclusion
• FAQ

What is Time in Range and why it matters

Time in Range (TIR) refers to the percentage of time a person’s glucose levels stay within a pre-specified target range — most commonly 70–180 mg/dL for nonpregnant adults with diabetes. With CGM, glucose is tracked continuously, day and night. This allows clinicians and patients to see not just an average glucose over months, but real-time glucose behavior — how often someone dips low, spikes high, or maintains stable glucose. Such granularity reveals patterns that A1C cannot show, including frequent hypo- or hyperglycemia, glycemic variability, and time spent above or below target.

International consensus recommendations generally set the TIR goal at ≥ 70% of the day (about 17 of 24 hours) within the 70–180 mg/dL range for many adults with type 1 or 2 diabetes.

Limitations of A1C that TIR can address

A1C — measuring glycated hemoglobin — remains valuable because it reflects the average glucose exposure over approximately 2–3 months. Nevertheless, A1C has important drawbacks:

First, it obscures variability. Two patients with the same A1C may have vastly different glucose patterns — one could have frequent highs and lows, the other more stable glucose. A1C misses these swings entirely.

Second, A1C can be misleading in certain conditions. For patients with anemia, altered red blood cell turnover, kidney disease, or hemoglobinopathies, A1C may over- or under-represent actual glycemic exposure.

Third, A1C does not help identify periods of hypoglycemia — a critical risk, especially in insulin-treated patients. Because hypoglycemia may be brief or occur at night, it may not significantly alter the average glucose, yet it poses real danger.

In contrast, TIR — by capturing continuous data — offers insight into both hyperglycemia and hypoglycemia, glycemic variability, and the effects of daily behaviors or treatment changes. For many clinicians, that makes it a more actionable metric.

How to interpret and apply TIR in clinical practice

Adopting TIR into routine practice requires a structured yet flexible approach.

First, define target ranges. For many adults, standard TIR targets are 70–180 mg/dL, with goals of ≥ 70% in range, less than 4% below 70 mg/dL (time below range, TBR), and a minimal proportion above 180 mg/dL (time above range, TAR).

Second, use CGM reports wisely. CGM devices typically produce an “ambulatory glucose profile” (AGP), summarizing daily patterns, variability, and glucose trends. Clinicians should review these reports with patients regularly — not as a once‑off snapshot, but as part of an ongoing conversation. This helps identify triggers for out-of-range glucose: meal composition, timing, insulin dose, physical activity, or sleep patterns.

Third, integrate TIR with A1C — rather than discard A1C entirely. While TIR offers rich daily detail, A1C retains value as a long-term, well-studied predictor of risk. Using both metrics provides a fuller picture, allowing for better-informed, personalized care goals.

Finally, tailor goals to the individual. Not every patient will aim for the same TIR — comorbidities, age, hypoglycemia risk, and access to CGM all influence target setting. Clinicians should coordinate with patients to set realistic and meaningful goals.

Evidence that TIR predicts long-term outcomes

Emerging research strongly supports TIR as a meaningful predictor of long-term complications. A 2025 study comparing TIR and “time in tight range (TITR)” found higher TIR was significantly associated with better achievement of glucose management indicator (GMI) and A1C targets among patients using CGM.

Moreover, guidance from the American Diabetes Association (ADA) notes that each 10% increase in TIR is associated with a meaningful reduction in risk for micro- and macrovascular complications.

The REALISM‑T1D study showed a strong correlation between TIR and A1C using 90-day CGM data, even in real-world settings. Because TIR captures day‑to‑day glucose behavior — including durations of hypo- and hyperglycemia — it may better reflect the glycemic exposures that drive complications than A1C’s three‑month average.

Challenges, limitations, and future directions

Despite its promise, TIR has some limitations.

First, standardization is still evolving. Different CGM devices may yield slightly different glucose readings, and definitions (exact thresholds, time windows) may vary between clinical settings.

Second, TIR doesn’t fully capture variability or severity of excursions. For example, time just above 180 mg/dL and time above 250 mg/dL both count as “out of range,” but have different implications.

Third, while outcome data is growing, A1C remains more established in long-term research. And for patients without CGM access, TIR remains difficult to track.

Nonetheless, research into refined metrics like TITR and advanced concepts like “glucodensity” continues to expand how we view glucose patterns and risk.

Conclusion

Time in Range offers a deeper, richer understanding of glycemic control than A1C alone. By capturing real‑time glucose trends — including highs, lows, and variability — TIR helps patients and clinicians tailor treatment and lifestyle interventions more precisely.

While challenges remain around standardization, device variability, and long-term data, growing evidence suggests TIR may better predict complications and offer practical, actionable insights for everyday care. Using TIR alongside A1C supports a more complete, patient-centered approach to diabetes management.

FAQ

What is a good TIR target for most adults with diabetes?
A common goal is ≥ 70% of time spent between 70–180 mg/dL, with less than 4% below 70 mg/dL and minimal time above 180 mg/dL.

Does TIR replace A1C entirely?
Not yet. While TIR offers important dynamic information, A1C remains valuable due to its long-term evidence base. Using both is best practice.

Can TIR be used for type 2 diabetes as well as type 1?
Yes. TIR is useful for both types, particularly for those using insulin or at risk of glucose fluctuations.

What if a patient doesn’t use a CGM?
Without CGM, A1C and occasional glucose checks can help, but they provide less granularity. CGM access is key for tracking TIR.

Are there emerging metrics beyond TIR?
Yes. Newer tools like “time in tight range” and “glucodensity” are under study to provide deeper insight into glucose patterns and risks.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.